DeLisa Fairweather, PhD, is an Associate Professor of Medicine, Immunology and Clinical Translational Science at Mayo Clinic in Jacksonville, Florida and Director of Translational Research in the Department of Cardiovascular Medicine. Dr. Fairweather’s research focuses on mitochondrial dynamics and the regenerative potential of extracellular vesicles to prevent cardiovascular and chronic inflammatory diseases including myocarditis which she has been studying for 25 years receiving grants from the National Institutes of Health (NIH) and the American Heart Association (AHA). She is also an expert in understanding the role of sex differences in promoting health and disease with a focus on cardiovascular and autoimmune diseases. She is a co-founder of the Ehlers Danlos Syndrome Clinic at Mayo Florida where she is researching the mechanism leading to sex differences in hypermobility and a leader of the Mayo Clinic-led US Expanded Access Program for the use of convalescent plasma for patients with COVID-19 which enrolled 105,000 and transfused nearly 95,000 patients with severe and life-threatening COVID-19 showing that convalescent plasma is safe to administer and that high antibody levels reduce mortality. Ongoing studies are examining the efficacy of convalescent plasma in reducing mortality in COVID-19. She has published around 100 manuscripts with an H-index of 43.